Andrée-Anne Fournier
Education
M.A. and B.Sc., economics, Université Laval
Summary of Experience
Ms. Fournier, an economist with 20 years of consulting experience, has particular expertise in pharmaceuticals, medical devices, and health economics. She has led case teams and provided analyses in False Claims Act (FCA), Anti-Kickback Statute (AKS), and Racketeer Influenced and Corrupt Organizations (RICO) Act matters, including those involving alleged kickbacks, off-label marketing, misbranding, and pricing issues, among others. She has assisted testifying experts in the preparation of reports, testimony, and related analyses in connection with class certification, liability, and damages. She has also directed economic and statistical analyses for a wide variety of health care-related litigations, including analyses of large datasets and government and private administrative claims records. Ms. Fournier has presented a number of abstracts at health care conferences in the US and Canada and published research on cost of illness, drug cost effectiveness, and other topics in health economics. Her coauthored articles on the economic impact of major depressive disorder have been published in peer-reviewed journals such as the Journal of Clinical Psychiatry and PharmacoEconomics.
-
Impact of living with an adult with depressive symptoms among households in the United States
Journal of Affective Disorders, 2024
2024Greenberg P, O'Callaghan L, Fournier AA, Gagnon-Sanschagrin P, Maitland J, Chitnis A
-
Economic Considerations Related to Biosimilar Market Entry
American Bar Association Antitrust Law Section, 2024
2024 -
The Economic Burden of Adults with Major Depressive Disorder in the United States (2019)
Advances in Therapy, 2023
2023Greenberg P, Chitnis A, Louie D, Suthoff E, Chen SY, Maitland J, Gagnon-Sanschagrin P, Fournier AA, Kessler RC
-
The Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018)
PharmacoEconomics, 2021
2021Greenberg P, Fournier A, Sisitsky T, Simes M, Berman R, Koenigsberg S, Kessler R
-
Special Issue of PharmacoEconomics on Major Depressive Disorders
PharmacoEconomics (2021) 39:617
2021 -
The Economic Burden of Adults With Major Depressive Disorder in the United States (2005 and 2010)
J Clin Psychiatry 2015 Feb;76(2):155-73
2015Greenberg P, Fournier A, Sisitsky T, Pike C, Kessler R
-
The Economic Impact of Pre-Dialysis Epoetin Alfa on Health Care and Work Loss Costs in Chronic Kidney Disease: An Employer's Perspective
Disease Management 2008 Feb;11(1):49-58
2008Moyneur E, Bookhart BK, Mody SH, Fournier AA, Mallett D, Duh MS
-
The Value Of Antihypertensive Drugs: A Perspective On Medical Innovation
Health Affairs
2007Cutler D, Long G, Berndt E, Royer J, Fournier A, Sasser A, Cremieux P
-
Medical and work loss burden of pre-dialysis chronic kidney disease and related anemia: an employer's perspective
Journal of Health & Productivity 2007 (Oct): 3-9
2007Moyneur E, Bookhart B, Mody SH, Fournier A, Mallet D, Duh MS
-
Prevalence, referral patterns, testing, and surgery in aortic valve disease: leaving women and elderly patients behind?
J Heart Valve Dis 2007 Jul;16(4):362-9
2007Bach D, Ivanova J, Birnbaum H, Fournier A, Tuttle E
-
The Impact of Antihypertensive Drugs on the Number and Risk of Death, Stroke, and Myocardial Infarction in the United States
National Bureau of Economic Research Working Paper
2006Berndt E, Sasser A, Long G, Cremieux P, Royer J, Fournier AA
-
November 20, 2024
-
October 16, 2024
-
October 17, 2023
-
June 14, 2021
-
May 5, 2021